Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

BACKGROUND: Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway. In preclinical studies, the pan-PI3K inhibitor buparlisib showed antitumour activity in glioma models. METHODS: This was a two-part, multicentre, phase Ib/II study in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, Mark, Clement, Paul M, Campone, Mario, Gil-Gil, Miguel J, DeGroot, John, Chinot, Olivier, Idbaih, Ahmed, Gan, Hui, Raizer, Jeffrey, Wen, Patrick Yung, Pineda, Estela, Donnet, Valerie, Mills, David, El-Hashimy, Mona, Mason, Warren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359195/
https://www.ncbi.nlm.nih.gov/pubmed/32665311
http://dx.doi.org/10.1136/esmoopen-2020-000672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359195/
https://www.ncbi.nlm.nih.gov/pubmed/32665311
http://dx.doi.org/10.1136/esmoopen-2020-000672

Ejemplares similares